Mar 3, 2026 08:45AM
Jan 28, 2026 08:45AM
Jan 28, 2026 08:45AM
Dec 9, 2025 05:45PM
Dec 9, 2025 05:45PM
Dec 7, 2025 06:20PM
Dec 7, 2025 06:20PM Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Dec 7, 2025 06:15PM
Dec 7, 2025 06:15PM
Nov 12, 2025 08:45AM
Nov 12, 2025 08:45AM
Nov 3, 2025 08:45AM
Nov 3, 2025 08:45AM
Nov 3, 2025 08:45AM Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Nov 3, 2025 08:45AM
Oct 14, 2025 08:45AM
Oct 6, 2025 04:05PM
Oct 1, 2025 08:45AM
Sep 18, 2025 01:30PM
Sep 18, 2025 01:30PM
Sep 11, 2025 09:15AM Nancy Chang joins Immix Biopharma board of directors
Sep 11, 2025 09:15AM
Sep 8, 2025 04:05PM
Sep 8, 2025 04:05PM
Aug 25, 2025 09:30AM
Aug 6, 2025 12:31PM
Aug 6, 2025 12:30PM
Jul 11, 2025 09:36AM Immix Biopharma reports absence of neurotoxicity in CAR-T trial
Jul 11, 2025 09:36AM
Jul 8, 2025 06:51AM
Jul 7, 2025 09:35AM
Jul 7, 2025 09:35AM
Jun 6, 2025 09:39AM
Jun 3, 2025 02:56PM
Jun 3, 2025 02:55PM Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
May 23, 2025 09:06AM
May 23, 2025 09:05AM
May 22, 2025 04:05PM
May 22, 2025 04:02PM
May 21, 2025 04:03PM
Apr 23, 2025 10:04AM
Feb 11, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Immix Biopharma, Inc. (IMMX)
Feb 10, 2025 09:35AM
Feb 10, 2025 09:35AM
Jan 7, 2025 09:34AM
Jan 7, 2025 09:34AM
Dec 19, 2024 09:35AM
Dec 19, 2024 09:35AM
Dec 16, 2024 09:48AM Immix Biopharma (IMMX): Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Dec 16, 2024 09:48AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All